Citadel Advisors
MBOT icon

Citadel Advisors’s Microbot Medical MBOT Stock Holding History

Citadel Advisors’s Portfolio MBOT Stock Details MBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$250K Buy
103,800
+3,400
+3% +$7.59K ﹤0.01% 10909
2025
Q4 		$201K Sell
100,400
-142,300
-59% -$337K ﹤0.01% 11038
2025
Q3 		$740K Buy
242,700
+154,100
+174% +$481K ﹤0.01% 8214
2025
Q2 		$223K Buy
88,600
+41,300
+87% +$98.8K ﹤0.01% 10452
2025
Q1 		$71.4K Buy
+47,300
New +$83.6K ﹤0.01% 11886
2024
Q1 		– Sell
-4,700
Closed -$7.71K – 15124
2023
Q4 		$7.71K Buy
+4,700
New +$6.26K ﹤0.01% 13272

Other funds holding MBOT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CBU
CIBC Bancorp USA Chicago, Illinois $74.4B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DnB Asset Management
DnB Asset Management Oslo, Norway $28B AUM 26% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Citadel Advisors's MBOT Position: Q1 2024 in Review

Citadel Advisors sold out of Microbot Medical (MBOT) in Q1 2024, closing a stake of 18,039 shares — an estimated $29.6K sold.

Citadel Advisors first reported a position in MBOT in Q2 2013 and held it in 19 quarters. The position peaked at $140K in Q1 2021. 33 funds tracked by Wall St. Rank hold MBOT as of Q1 2024.

  • Citadel Advisors reported no remaining Microbot Medical position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 18,039 Microbot Medical shares in Q1 2024, an estimated $29.6K.
  • Citadel Advisors first reported a position in Microbot Medical in Q2 2013 and held it in 19 quarters.
  • Citadel Advisors's Microbot Medical position peaked at $140K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Microbot Medical as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.